Anti-Cancer Treatment Strategies in the Older Population: Time to Test More?

Aging is a well-recognized risk factor for the development of cancer. The incidence of new cancer diagnoses has increased globally given the rising senior population. Many hypotheses for this increased risk have been postulated over decades, including increased genetic and epigenetic mutations and the concept of immunosenescence. The optimal treatment strategies for this population with cancer are unclear. Older cancer patients are traditionally under-represented in clinical trials developed to set the standard of care, leading to undertreatment or increased toxicity. With this background, it is crucial to investigate new opportunities that belong to the most recent findings of an anti-cancer agent, such as immune-checkpoint inhibitors, to manage these daily clinical issues and eventually combine them with alternative administration strategies of antiblastic drugs such as metronomic chemotherapy.

Automated summary

Aging is a recognized risk factor for cancer development, but older cancer patients are often underrepresented in clinical trials, leading to inadequate treatment or increased toxicity. Exploring new opportunities and combining different treatment strategies becomes crucial in managing these daily clinical issues.